Stockscreener 앱 받기
188.93
0.27%
0.51
시간 외 거래:
188.93
Astrazeneca Plc 주식(AZN)의 최신 뉴스
AstraZeneca Expands Real-World Push With New China Kidney Registry - TipRanks
AstraZeneca’s REVIVE Trial Targets Relapse After Osimertinib, Extending the Lung Cancer Playbook - TipRanks
AstraZeneca to boost cell therapy capabilities with new China investment - BioPharma Dive
Jacobio Pharma Poised To Turn A Profit From Precision Cancer Drugs - Benzinga
Wilmington Savings Fund Society FSB Cuts Stock Position in Astrazeneca Plc $AZN - MarketBeat
Hudson Bay Capital Management LP Acquires 128,256 Shares of Astrazeneca Plc $AZN - MarketBeat
AstraZeneca to build cell therapy base, innovation centre in Shanghai - marketscreener.com
AstraZeneca Makes Soliris Available In Malaysia For Rare Disease Treatment - bernama
Cowen Maintains AZN AstraZeneca PLC at Buy on March 18, 2026 - Meyka
AstraZeneca: The $6 Billion Imfinzi Story Is Expanding Beyond Lung Cancer - Smartkarma
Challenges for AstraZeneca (AZN) Amid Drug Pricing Claims - GuruFocus
Why AstraZeneca PLC (AZN) is one of the best immunotherapy stocks to buy according to hedge funds - MSN
Astrazeneca Plc $AZN Shares Sold by CIBC Private Wealth Group LLC - MarketBeat
AstraZeneca PLC (LON:AZN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
AstraZeneca Advances Primary Care Lung Diagnosis Study With Global Reach - TipRanks
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU - TradingView
Sentiment Recap: Why is AstraZeneca PLC Depositary Receipt stock going up2026 Market Trends & Fast Gain Swing Alerts - baoquankhu1.vn
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
AstraZeneca (AZN) Faces Potential Impact from Recent Federal Rul - GuruFocus
Can AstraZeneca PLC Depositary Receipt expand into new marketsTrend Reversal & Real-Time Stock Entry Alerts - baoquankhu1.vn
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp - Insider Monkey
AstraZeneca receives EU approval for Imfinzi in early gastric cancer By Investing.com - Investing.com South Africa
AstraZeneca's Imfinzi Gets Expanded EU Label With Approval for Gastric Cancer -- Update - marketscreener.com
EU backs AstraZeneca (NYSE: AZN) Imfinzi for early gastric and GEJ cancers - Stock Titan
AstraZeneca (AZN) Gains EU Approval for Imfinzi in Cancer Treatm - GuruFocus
AstraZeneca PLC Stock (ISIN: US6549022043) Gains Momentum on EU Imfinzi Approval for Gastric Cancer - AD HOC NEWS
EU Approves AstraZeneca's Imfinzi Combo as First Perioperative Treatment for Early Gastric Cancer - marketscreener.com
Holocene Advisors LP Acquires 1,807,565 Shares of Astrazeneca Plc $AZN - MarketBeat
Fayez Sarofim & Co Has $298.78 Million Position in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca's Imfinzi receives EU approval - Sharecast.com
Centiva Capital LP Takes Position in Astrazeneca Plc $AZN - MarketBeat
Capitolis Liquid Global Markets LLC Purchases New Stake in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca Plc $AZN Shares Purchased by Bamco Inc. NY - MarketBeat
Bank of America Corp DE Boosts Holdings in Astrazeneca Plc $AZN - MarketBeat
ASTRAZENECA : Berenberg keeps its Buy rating - marketscreener.com
EU Approves AstraZeneca’s Imfinzi With FLOT Chemotherapy For Early Gastric Cancer - DirectorsTalk Interviews
Ameriprise Financial Inc. Boosts Stock Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca's Imfinzi Combo Receives EU Approval for Early Gastric Cancer - marketscreener.com
Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers - AstraZeneca
AstraZeneca PLC Stock (ISIN: US6549022043) Faces Valuation Scrutiny Amid Strong Oncology Momentum - AD HOC NEWS
AstraZeneca Abivax Talks Highlight Biotech Expansion And Valuation Upside Potential - Yahoo Finance
AstraZeneca PLC (AZN) Secures US Priority Review For Candidate Breast Cancer Treatment - Insider Monkey
AstraZeneca PLC Stock (ISIN: US6549022043) Under Pressure as Sector Headwinds Mount - AD HOC NEWS
Astrazeneca Plc $AZN Shares Sold by Elevation Point Wealth Partners LLC - MarketBeat
Crawford Investment Counsel Inc. Buys 27,213 Shares of Astrazeneca Plc $AZN - MarketBeat
Calydon Capital Has $830,000 Stake in Astrazeneca Plc $AZN - MarketBeat
Cinctive Capital Management LP Boosts Stake in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca Plc $AZN Shares Bought by Clark Capital Management Group Inc. - MarketBeat
AZN Stock Quote Price and Forecast - CNN
Market Outlook: Should I hold or sell AstraZeneca PLC Depositary Receipt nowQuarterly Trade Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
Towarzystwo Funduszy Inwestycyjnych PZU SA Sells 12,300 Shares of Astrazeneca Plc $AZN - MarketBeat
Wellington Management Group LLP Has $2.48 Billion Holdings in Astrazeneca Plc $AZN - MarketBeat
Sanders Capital LLC Sells 468,180 Shares of Astrazeneca Plc $AZN - MarketBeat
Tepp RIA LLC Invests $1.07 Million in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca Plc $AZN Shares Acquired by Integral Health Asset Management LLC - MarketBeat
Capital Wealth Planning LLC Has $8.03 Million Stock Holdings in Astrazeneca Plc $AZN - MarketBeat
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline - AOL.com
Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart
AstraZeneca (LSE:AZN) Valuation Insights After Recent Price Moves - Kalkine Media
Mackenzie Financial Corp Raises Position in Astrazeneca Plc $AZN - MarketBeat
Capital World Investors Purchases 940,062 Shares of Astrazeneca Plc $AZN - MarketBeat
AZN Stock Price and Chart — LSE:AZN - TradingView
AstraZeneca’s DURGA-4 CAR-T Study Puts New Pressure on Multiple Myeloma Rivals - TipRanks
AstraZeneca Advances Pediatric Symbicort Device Study, Supporting Long Term Respiratory Strategy - TipRanks
AstraZeneca (AZN) Refutes Takeover Speculation - GuruFocus
$100 Million AstraZeneca Deal Puts Chinese Biotech Jacobio on Path to Profit - Caixin Global
Abivax denies AstraZeneca takeover rumors reported by French media - Reuters
1.08%
자본화:
|
볼륨(24시간):